以岭药业品牌怎么样 申请店铺

我要投票 以岭药业在中草药行业中的票数:699 更新时间:2026-01-08
以岭药业是哪个国家的品牌?「以岭药业」是 石家庄以岭药业股份有限公司 旗下著名品牌。该品牌发源于河北,由创始人吴相君在2001期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力以岭药业品牌出海!将品牌入驻外推网,定制以岭药业品牌推广信息,可以显著提高以岭药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

以岭药业怎么样

国家重点高新技术企业--石家庄以岭药业股份有限公司由中国工程院吴以岭院士创建,在他的领导下,以岭药业始终坚持以科技为先导,以市场为龙头的科技创新发展战略,创立"理论-科研-新药-生产-营销"五位一体的独特运营模式,建立起以中医络病理论创新为指导的新药研发创新技术体系。

在以岭药业的发展历程中,凝聚了一大批科研、管理、生产、营销精英,包括归国专家、外籍专家、博士、硕士及各类高职人才,为河北医科大学培养博士、硕士研究生,被国家人事部批准为博士后科研工作站。

以岭药业以络病理论创新带动中医药产业化,运用现代高新技术研发现代中药、西药、和生物药,研发国家专利新药9个,覆盖心脑血管疾病、感冒呼吸疾病、肿瘤、糖尿病及其并发症等重大疾病领域。通过国家GMP认证的中药生产线、通过欧盟认证的化学制剂生产车间具有年产值达50亿的生产能力。以岭药业为国家创新型企业、中国制药工业50强,以岭商标成为中国驰名商标。

国家科技部前领导曾赞誉五位一体的发展模式为"我国中医药科技成果产业化的创举"。

以岭药业立足国内、接轨国际,在石家庄、北京大兴、密云建立了三个国际标准的科研生产基地,通过了欧盟、新西兰等GMP认证。科研、生产、质检、贸易、管理人才全部具有国际化背景,构建了符合国际药品标准的生产、质控体系。依靠现代高新技术与设备和完善的药品生产质量控制体系,生产高品质中药与西药。产品已经出口到英国、美国、西班牙、韩国、日本、俄罗斯、新西兰等许多国家。

位于北京生物工程与医药产业基地的北京以岭药业,占地210亩,为国家重点高新技术企业,主要生产面向国际市场的植物药、保健品、膳食补充剂。

位于北京密云的北京以岭生物按照欧美GMP标准建设,主要生产面向国际市场的激素、肿瘤类药物和具有自主知识产权的新制剂。

Shijiazhuang Yiling Pharmaceutical Co., Ltd, a national key high-tech enterprise, was founded by Academician Wu Yiling of Chinese Academy of engineering. Under his leadership, Yiling pharmaceutical always adheres to the development strategy of scientific and technological innovation with science and technology as the guide and market as the leader, creates a unique operation mode of "theory research new medicine production marketing" and establishes a theoretical innovation of traditional Chinese medicine collateral disease as the reference New drug R & D innovation technology system. In the development process of Yiling pharmaceutical industry, a large number of scientific research, management, production and marketing elites, including returned experts, foreign experts, doctors, masters and all kinds of higher vocational talents, have been gathered, training doctors and masters for Hebei Medical University, and approved by the Ministry of human resources as post doctoral research workstation. Lingyao promotes the industrialization of traditional Chinese medicine with the innovation of collateral disease theory, develops modern Chinese medicine, western medicine and biological medicine with modern high and new technology, and develops 9 new national patent drugs, covering the major disease fields such as cardio cerebrovascular disease, cold and respiratory disease, tumor, diabetes and its complications. The production line of traditional Chinese medicine certified by national GMP and the chemical production workshop certified by European Union have an annual output value of 5 billion. Take Ling pharmaceutical as a national innovative enterprise and top 50 pharmaceutical industry in China, and take Ling trademark as a well-known trademark in China. Former leaders of the Ministry of science and technology of the people's Republic of China once praised the five in one development mode as "the pioneering work of industrialization of scientific and technological achievements of traditional Chinese medicine". Based on domestic and international standards, Yiling pharmaceutical has established three international standard research and production bases in Shijiazhuang, Beijing Daxing and Miyun, and has passed GMP certification of EU, New Zealand, etc. The talents of scientific research, production, quality inspection, trade and management all have international background, and the production and quality control system in line with international drug standards has been established. Relying on modern high-tech and equipment and perfect quality control system of drug production, we can produce high-quality traditional Chinese medicine and Western medicine. The products have been exported to the United Kingdom, the United States, Spain, South Korea, Japan, Russia, New Zealand and many other countries. Located in Beijing bioengineering and pharmaceutical industry base, Beijing Yiling pharmaceutical, covering an area of 210 mu, is a national key high-tech enterprise, which mainly produces plant medicine, health care products and dietary supplements for the international market. Beijing Yiling biology, located in Miyun, Beijing, is built in accordance with European and American GMP standards. It mainly produces hormones, tumor drugs and new preparations with independent intellectual property rights for the international market.

本文链接: https://brand.waitui.com/887854f10.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

温氏股份:2025年净利同比预降40.73%—46.12%

36氪获悉,温氏股份发布业绩预告,预计2025年归母净利50亿元—55亿元,同比下降40.73%—46.12%。报告期内,公司强抓基础生产管理和重大疫病防控等工作,大生产保持稳定,核心生产指标持续优化,公司养殖成本同比下降,但由于生猪销售价格同比出现较大幅度下降,公司生猪养殖业务利润同比下降。报告期内,公司养鸡业务生产持续保持高水平稳定,但由于毛鸡销售价格同比下跌,公司肉鸡养殖业务利润同比下降。

2小时前

盈富基金遭南向资金净卖出62.84亿港元

南向资金今日净卖出49.01亿港元,盈富基金、南方恒生科技、恒生中国企业分别遭净卖出62.84亿港元、12.88亿港元、12.50亿港元。净买入方面,小米集团-W、腾讯控股、中芯国际净买入额位列前三,分别获净买入10.72亿港元、8.64亿港元、5.63亿港元。(第一财经)

2小时前

智明达:未来将继续加大商业航天领域的投入与布局

36氪获悉,智明达在互动平台表示,公司预计2026年商业航天业务有高速增长。公司在2022年已布局商业航天领域相关业务,目前已成功参与商业运载火箭发动机综合控制、商业卫星数据链、商业卫星地面站的高性能计算、路由管控等配套。根据国家发展战略导向,公司未来将继续加大商业航天领域的投入与布局,提升商业航天领域产品收入在公司收入中的占比。

2小时前

中国广核:2025年核电机组总发电量同比增长2%

36氪获悉,中国广核公告,根据公司统计,2025年1月至12月份,公司及其子公司运营管理的核电机组总发电量约为2470.13亿千瓦时,较去年同期增长2%。总上网电量约为2326.48亿千瓦时,较去年同期增长2.36%。

2小时前

胜通能源:不涉及机器人相关业务

36氪获悉,胜通能源发布异动公告,公司股票价格自2025年12月12日至2026年1月8日累计涨幅为307.05%,目前公司股价已严重偏离上市公司基本面,未来存在快速下跌的风险。公司已停牌核查并复牌,未来可能再次停牌。公司不涉及机器人相关业务,公司主营业务仍为液化天然气采购、运输及销售,未发生重大变化。收购方七腾机器人参与本次收购的资金来源为自有资金及自筹资金,截至目前,自筹资金的申请仍在审批阶段,是否可以申请成功尚存在不确定性。

2小时前

本页详细列出关于以岭药业的品牌信息,含品牌所属公司介绍,以岭药业所处行业的品牌地位及优势。
咨询